Metis TechBio Co (FRA:RO9) Short-Term Debt: €4.85 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RO9 Metis TechBio Co Ltd FRA:RO9
17 GF Score
Price €1.31
! 1 Warning Sign
View Full Analysis

What is Metis TechBio Co Short-Term Debt?

Metis TechBio Co FRA:RO9 +7.99% 17 Short-Term Debt is €4.85 Mil as of Dec. 2025. GuruFocus rates FRA:RO9 with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Metis TechBio Co's Short-Term Debt for the quarter that ended in Dec. 2025 was €4.85 Mil.

Metis TechBio Co's quarterly Short-Term Debt increased from Dec. 2024 (€1.31 Mil) to Sep. 2025 (€4.78 Mil) and increased from Sep. 2025 (€4.78 Mil) to Dec. 2025 (€4.85 Mil).

Metis TechBio Co's annual Short-Term Debt declined from Dec. 2023 (€3.85 Mil) to Dec. 2024 (€1.31 Mil) but then increased from Dec. 2024 (€1.31 Mil) to Dec. 2025 (€4.85 Mil).

Metis TechBio Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Metis TechBio Co Short-Term Debt Related Terms

Metis TechBio Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Metis TechBio Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metis TechBio Co Short-Term Debt Chart

Metis TechBio Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Short-Term Debt
77.43 3.85 1.31 4.85

Metis TechBio Co Quarterly Data
Dec22 Dec23 Dec24 Sep25 Dec25
Short-Term Debt 77.43 3.85 1.31 4.78 4.85
FRA:RO9
17GF Score
Metis TechBio Co Ltd FRA:RO9
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €4.85 Mil mean?
Metis TechBio Co (FRA:RO9) has a Short-Term Debt of €4.85 Mil as of Dec. 2025.
Is Metis TechBio Co's Short-Term Debt too high?
Metis TechBio Co's current Short-Term Debt is €4.85 Mil. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's Short-Term Debt compare to VRTX and REGN?
Metis TechBio Co's Short-Term Debt of €4.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Metis TechBio Co's current Short-Term Debt is €4.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current Short-Term Debt of €4.85 Mil. The current Short-Term Debt is €4.85 Mil. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current Short-Term Debt is €4.85 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metis TechBio Co Business Description

Other Exchanges 07666:Hong Kong
Address No. 21 Tianhe West Road, Room 201, 2nd Floor, Building 13, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing, CHN
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score

Get the complete analysis for FRA:RO9

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price